| To: tuck who wrote (8) | 12/28/2000 4:36:39 PM | | From: JR | | | | Tuck,
You make some good points. Only the highly visible, widely followed biotechs are acting well right now. EBIO is in neither group. Their niche is a good one, though, and they should become recognized for the company they keep...Applied Biosystems. Second deal was with Third Wave. Company is about to complete a third deal shortly.
They said the manufacturing acquisition would take 2001 revenues up from just under $4 million to $11 million with a loss of about 11 cents per share. Auerbach was showing a loss of 9 cents in 2001 on $3.8 million revenues.
The key is, how quickly they can accelerate demand for their probes. At some point between $11 to $20 million in volume, they will clearly go profitable if they control costs. The markets they serve are and will continue to grow very quickly (+30%/yr.) according to most forecasts.
$5 share purchases this week might look very good a few months out from now. Also, recent favorable mention about Epoch in NYTimes Biotech article where a fund manager was buying it recently as it was at attractive pricing below $8 or so.
Appreciate any additional information you can provide. Thanks |
| | EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: tuck who wrote (2) | 1/2/2001 2:32:24 PM | | From: JR | | | | Tuck-still interested in Auerbach's estimate of EBIO's 2001 losses, which you said he increased "dramatically". In his earlier report, he had a 9 cents loss per share on $3.8 million in revenues. EBIO has increased the revenue estimate to $11 million for 2001. So, where did he take the earnings loss to and based on what?
Thanks |
| | EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: JR who wrote (10) | 1/2/2001 2:57:36 PM | | From: tuck | | | | OK,
If you followed the link in post #4, you would see the revision occurred roughly a month ago. That's the time frame I know of. The one analyst has to be Auerbach. Look in the "consensus EPS trend" frame (center left):
biz.yahoo.com
Haven't seen an actual report, so I don't know what he based it on. I concur with Peter that the acquisition should not be that big a hit. Whatever, the change from a loss of four cents to a loss of eleven counts as dramatic, in my book. Apologies if this is old stuff to you, but hopefully I've made clearer what I was talking about.
Of course, it wouldn't be the first time Yahoo's data was slightly off. If you can share better data, please do.
Cheers, Tuck |
| | EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: tuck who wrote (11) | 1/2/2001 8:03:19 PM | | From: JR | | | | Tuck--Thanks for identifying your souce (Yahoo).
The FSVK (Auerbach) report issued Aug. 11, 2000 projects negative earnings 9 cents/share for 2001. I don't know where Yahoo got 4 cents. An increase from 9 cents to 11 cents is significant, but nothing like an increase from 4 to 11.
Auerbach estimates that when total revenues hit $14 - 22 million annually, EBIO can earn from 25 cents to 52 cents per share. Given that management has revised upward the 2000 revenue projection to $11 million during the November cc, they are getting close to profitability. Their plan to market and sell a line of probes could speed this process up, especially if their reagents, etc. are as enabling to a variety of users as Auerbach explained in his report. |
| | EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: JR who wrote (12) | 3/9/2001 4:03:46 PM | | From: tuck | | | | JR,
Given that management has revised upward the 2000 revenue projection to $11 million during the November cc, they are getting close to profitability.
>>Epoch Biosciences Announces Fourth Quarter and Fiscal 2000 Financial Results
BOTHELL, Wash., March 6 /PRNewswire/ -- Epoch Biosciences, Inc. (Nasdaq: EBIO - news), a developer of proprietary chemistry with commercial applications in the fields of genomics and molecular diagnostics and a manufacturer of specialty oligonucleotides, today reported financial results for its fourth quarter and fiscal year ended December 31, 2000. Net loss for the fourth quarter was $1.4 million, or $0.05 per share, compared with net loss of $1.4 million, or $0.08 per share, in the fourth quarter of 1999. For the fiscal year ended December 31, 2000, net loss was $4.9 million, or $0.20 per share, compared with a net loss of $4.7 million, or $0.30 per share, for the 1999 fiscal year.
Revenues for the fourth quarter were $945,000 compared to $11,000 in the fourth quarter of 1999, reflecting the sale of chemical intermediates to Applied Biosystems, increased product revenues from the acquisition of Synthetic Genetics, a provider of a broad line of specialty oligonucleotides to the research market, and increased contract research revenues. For fiscal 2000, revenues were $1.4 million, compared to $181,000 for fiscal 1999. The increased revenues in 2000 primarily reflect the sale of chemical intermediates to Applied Biosystems, and increased product revenues from the acquisition of Synthetic Genetics. The Synthetic Genetics acquisition closed November 15, 2000, and was accounted for as a purchase. Accordingly, Epoch's results of operations for the fourth quarter and year ended December 31, 2000 includes the results at Synthetic Genetics for the 45-day period from November 16 through December 31, 2000.
At December 31, 2000, the Company held cash and cash equivalents of $12.1 million, up from $1.8 million at December 31, 1999.
Fourth Quarter and Full Year 2000 Highlights
``The fourth quarter of 2000 saw significant transition at Epoch with several positive strategic and operational developments,'' commented William G. Gerber, M.D., chief executive officer of Epoch. ``Primary among those are the acquisition of Synthetic Genetics in November, enabling the company to dramatically increase its oligonucleotide manufacturing capacity, the execution of a development, licensing and supply agreement with Third Wave Technologies, and the completion and occupancy of the company's new research and development and headquarters facilities in Bothell, Washington.''
``The acquisition of Synthetic Genetics of San Diego, California, a manufacturer of specialty oligonucleotides, gives us the ability to manufacture TaqMan® probes for Applied Biosystems and to introduce our own proprietary line of probes for genetic analysis to the marketplace, currently planned for the second half of 2001,'' said Sanford S. Zweifach, Epoch's President.
Additional significant accomplishments during the year included:
* Raising $10 million in a private equity financing from a group of
prominent investors, and $9.5 million from the exercise of warrants,
thereby facilitating re-listing on the Nasdaq National Market, and
providing the capital resources to accelerate research and pursue the
full commercial potential of the Company's technologies;
* Forming a strategic alliance with Specialty Laboratories to jointly
develop assays to test for residual human leukemias;
* Significantly expanding the strategic alliance with Applied Biosystems
to incorporate Epoch's technology in the entire line of Applied
Biosystems TaqMan® reagent products, and to provide Epoch with rights
to manufacture a percentage of MGB TaqMan® probes sold by Applied
Biosystems; and
* Receiving several patents on Epoch's technologies, including its Minor
Groove Binder compounds and the use of modified nucleotide in DNA
probes to detect single nucleotide polymorphisms (SNP's).
Outlook for 2001
``Calendar 2000 was a great year for Epoch, a year in which we laid the foundation for Epoch's future growth. We anticipate another exciting year for Epoch in 2001. We enter the year with the capital resources and product strategy necessary to capitalize on the large market opportunity for reagents for genetic analysis. Further, we have recently added to the management team that is charged with executing the strategy,'' said Gerber.<<
snip
>>Epoch Biosciences, Inc.
Statements of Operations
(dollars in thousands, except per share data)
3 Months Ended December 31, Years Ended December 31,
2000 1999 2000 1999
(unaudited) (unaudited)
Revenues $945 $11 $1,367 $181
Operating expenses:
Cost of product revenue 317 -- 317 --
Research and
development 1,013 725 3,468 2,858
Selling, general
and administrative 1,237 331 3,390 1,102
Total operating
expenses 2,567 1,056 7,175 3,960
Operating loss (1,622) (1,045) (5,808) (3,779)<<
snip again, emphasis mine
Revenues for the year were less than 1.4 million. So it looks like management's revised guidance was way, way, off. I'm guessing you heard management's figure for cash, not revenue. At least, I hope that's the explanation. I'll give the CC a listen this weekend. In any case, it doesn't look like they're near profitabilty or credibility (if they really said $11 million in '00 revenue) any time soon.
Cheers, Tuck |
| | EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: JR who wrote (14) | 6/14/2001 2:47:14 PM | | From: tuck | | | | Not exactly a mover of stock price, but nice to know EBIO has quality chemists, a good prize these days.
>>BOTHELL, Wash., June 14 /PRNewswire/ -- Epoch Biosciences, Inc. (Nasdaq: EBIO - news), a leading provider of proprietary chemistries and reagents that enable genomic research, announced that four of its research scientists were selected as honorees of the 2001 American Chemical Society's (ACS) 56th Northwest Regional Industrial Innovation Award for their discovery of a new class of DNA probes for genetic analysis. The four honorees are: Dr. Igor V. Kutyavin, Dr. Sergei Lokhov, Dr. Eugene Lukhtanov and Dr. Michael Reed, according to William G. Gerber, M.D., chief executive officer of Epoch.
The ACS award recognizes individuals in the Northwest whose creative innovations have contributed to the commercial success of their company and the betterment of the community. The Epoch team discovered a class of DNA probes with attached minor groove binder ligands (MGB probes) that improve current methods of genetic analysis.
The award program, to be held at Seattle University tomorrow, will include a symposium where the honorees will make a technical presentation, as well as an awards ceremony and reception.
Gerber commented, ``We are extremely proud that four of our colleagues were selected by the American Chemical Society as recipients of their prestigious award. The scientific research conducted at Epoch is essential to the success of our business. It is exciting that their peers in the scientific community recognize the hard work and innovation of these individuals.''<<
snip
Cheers, Tuck |
| | EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: tuck who wrote (15) | 4/17/2002 3:56:42 PM | | From: shearson | | | | Live Webcast of Epoch BioSciences, Inc. Q1 Earnings.
Epoch BioSciences, Inc. holds a live webcast of their Q1 Earnings conference call. This takes place on Tuesday, April 23rd at 11:00 AM EST at the following link:
viavid.com
Join us for the Live Event at 11:00 AM EST. A replay will be available at the same link as above for 10 days from the conference date if you miss the live version.
Epoch Biosciences, Inc., formerly Epoch Pharmaceuticals, Inc., is developing and commercializing proprietary technologies to enhance the study of genes. Its scientists are applying their expertise in nucleic acid chemistry to develop products that improve methods of studying the genetic sequence (genomes) of humans, animals and plants.
ViaVid Broadcasting, Inc. provides teleconferencing and webcasting services to corporate clients throughout North America. These services utilize systems that integrate traditional telephony technology with powerful streaming media technology and Web-based tools. From a simple conference call to a dynamic online presentation, our clients are able to choose the communication solution that best meets their unique needs. ViaVid's communications expertise and in-house technology allows the company to provide these services on a very cost competitive basis.
ViaVid is a newly listed (fully reporting) company on the OTC-BB under the symbol: VVDB |
| | EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: shearson who wrote (16) | 4/17/2002 4:08:38 PM | | From: tuck | | | | I don't suppose you'd listen and take notes. I'm going on a road trip tomorrow, and will miss the earnings report from this and other similar companies that I try to follow. Might make it back before the replay expires, but I'll have a backlog of CCs to listen to by then and don't know if I'll get to them all.
FWIW, I have covered past calls on the Trickle thread.
TIA & Cheers, Tuck |
| | EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| To: tuck who wrote (17) | 7/23/2002 12:15:02 PM | | From: shearson | | | | Live Webcast of Epoch BioSciences, Inc. Q2 Earnings.
Epoch BioSciences, Inc. holds a live webcast of their Q2 Earnings conference call. This takes place on Tuesday, July 30, 2002 at 11:00 AM EST at the following link:
viavid.com
Join us for the Live Event at 11:00 AM EST. A replay will be available at the same link as above for 45 days from the conference date if you miss the live version.
Epoch Biosciences, Inc., formerly Epoch Pharmaceuticals, Inc., is developing and commercializing proprietary technologies to enhance the study of genes. Its scientists are applying their expertise in nucleic acid chemistry to develop products that improve methods of studying the genetic sequence (genomes) of humans, animals and plants.
ViaVid Broadcasting, Inc. provides teleconferencing and webcasting services to corporate clients throughout North America. These services utilize systems that integrate traditional telephony technology with powerful streaming media technology and Web-based tools. From a simple conference call to a dynamic online presentation, our clients are able to choose the communication solution that best meets their unique needs. ViaVid's communications expertise and in-house technology allows the company to provide these services on a very cost competitive basis.
ViaVid is a newly listed (fully reporting) company on the OTC-BB under the symbol: VVDB |
| | EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
